CTLA4 and neoplasm: Anti–CTLA-4 therapy is capable of depleting Tregs in mouse tumor models and some human tumors, and while this is thought to be one of the major mechanisms of anti–CTLA-4 efficacy in mouse models, its role in human tumors is less clear (31–34).